Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kenneth Carl Anderson, M.D.

Co-Author

This page shows the publications co-authored by Kenneth Anderson and Constantine Mitsiades.
Connection Strength

10.271
  1. Mitsiades CS, Anderson KC. Epigenetic modulation in hematologic malignancies: challenges and progress. J Natl Compr Canc Netw. 2009 Nov; 7 Suppl 8:S1-12; quiz S14-6.
    View in: PubMed
    Score: 0.478
  2. Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G, Mateos MV, Richardson PG, Mollinedo F, San-Miguel JF, Anderson KC. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25.
    View in: PubMed
    Score: 0.435
  3. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell. 2004 Nov; 6(5):439-44.
    View in: PubMed
    Score: 0.338
  4. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):540-5.
    View in: PubMed
    Score: 0.318
  5. Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003 Oct 15; 63(20):6689-96.
    View in: PubMed
    Score: 0.314
  6. Mitsiades CS, Mitsiades N, Treon SP, Anderson KC. Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. Semin Oncol. 2003 Apr; 30(2):156-60.
    View in: PubMed
    Score: 0.303
  7. Mitsiades CS, Mitsiades N, Richardson PG, Treon SP, Anderson KC. Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):309-12.
    View in: PubMed
    Score: 0.303
  8. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83.
    View in: PubMed
    Score: 0.290
  9. Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
    View in: PubMed
    Score: 0.160
  10. Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC. Future agents and treatment directions in multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):127-41.
    View in: PubMed
    Score: 0.159
  11. Lawasut P, Groen RW, Dhimolea E, Richardson PG, Anderson KC, Mitsiades CS. Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets. Semin Oncol. 2013 Oct; 40(5):537-48.
    View in: PubMed
    Score: 0.157
  12. Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013 Jul; 37(7):829-37.
    View in: PubMed
    Score: 0.152
  13. Klippel S, Jakubikova J, Delmore J, Ooi M, McMillin D, Kastritis E, Laubach J, Richardson PG, Anderson KC, Mitsiades CS. Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol. 2012 Nov; 159(3):340-51.
    View in: PubMed
    Score: 0.146
  14. van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012; 4:253-68.
    View in: PubMed
    Score: 0.145
  15. Leiba M, Jakubikova J, Klippel S, Mitsiades CS, Hideshima T, Tai YT, Leiba A, Pines M, Richardson PG, Nagler A, Anderson KC. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol. 2012 Jun; 157(6):718-31.
    View in: PubMed
    Score: 0.142
  16. Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Redman KC, McKenney M, Warren D, Noonan K, Lunde L, Doss D, Colson K, Hideshima T, Mitsiades C, Munshi NC, Anderson KC. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
    View in: PubMed
    Score: 0.141
  17. McMillin DW, Delmore J, Negri JM, Vanneman M, Koyama S, Schlossman RL, Munshi NC, Laubach J, Richardson PG, Dranoff G, Anderson KC, Mitsiades CS. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8.
    View in: PubMed
    Score: 0.140
  18. McMillin DW, Jacobs HM, Delmore JE, Buon L, Hunter ZR, Monrose V, Yu J, Smith PG, Richardson PG, Anderson KC, Treon SP, Kung AL, Mitsiades CS. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther. 2012 Apr; 11(4):942-51.
    View in: PubMed
    Score: 0.139
  19. Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
    View in: PubMed
    Score: 0.138
  20. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.
    View in: PubMed
    Score: 0.136
  21. Richardson PG, Laubach J, Mitsiades CS, Schlossman R, Hideshima T, Redman K, Chauhan D, Ghobrial IM, Munshi N, Anderson KC. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
    View in: PubMed
    Score: 0.134
  22. McMillin DW, Delmore J, Negri J, Ooi M, Klippel S, Miduturu CV, Gray NS, Richardson PG, Anderson KC, Kung AL, Mitsiades CS. Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. PLoS One. 2011; 6(7):e20226.
    View in: PubMed
    Score: 0.134
  23. Jakubikova J, Cervi D, Ooi M, Kim K, Nahar S, Klippel S, Cholujova D, Leiba M, Daley JF, Delmore J, Negri J, Blotta S, McMillin DW, Hideshima T, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS. Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. Haematologica. 2011 Aug; 96(8):1170-9.
    View in: PubMed
    Score: 0.134
  24. Richardson PG, Laubach J, Mitsiades CS, Schlossman RL, Ghobrial IM, Munshi NC, Anderson KC. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
    View in: PubMed
    Score: 0.133
  25. Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011 May 10; 29(14):1916-23.
    View in: PubMed
    Score: 0.132
  26. Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011 Apr 28; 117(17):4409-19.
    View in: PubMed
    Score: 0.131
  27. McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb; 152(4):420-32.
    View in: PubMed
    Score: 0.130
  28. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 152(4):367-79.
    View in: PubMed
    Score: 0.130
  29. Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, Mitsiades CS, Anderson KC. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol. 2010 Aug; 150(4):438-45.
    View in: PubMed
    Score: 0.125
  30. Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson K. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
    View in: PubMed
    Score: 0.125
  31. Richardson P, Laubach J, Mahindra A, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Raje N, Munshi N, Anderson K. The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
    View in: PubMed
    Score: 0.124
  32. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
    View in: PubMed
    Score: 0.123
  33. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.
    View in: PubMed
    Score: 0.122
  34. Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G, Hideshima H, Munshi NC, Richardson PG, Carrasco DR, Anderson KC. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5.
    View in: PubMed
    Score: 0.122
  35. Richardson PG, Laubach J, Mitsiades C, Schlossman RL, Doss D, Colson K, McKenney ML, Noonan K, Warren DL, Ghobrial IM, Munshi NC, Anderson K. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
    View in: PubMed
    Score: 0.122
  36. Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw. 2010 Feb; 8 Suppl 1:S4-S12.
    View in: PubMed
    Score: 0.122
  37. Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
    View in: PubMed
    Score: 0.119
  38. Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CS. In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol. 2009 Dec; 147(5):672-6.
    View in: PubMed
    Score: 0.118
  39. McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009 Jul 15; 69(14):5835-42.
    View in: PubMed
    Score: 0.117
  40. Mitsiades CS, Hideshima T, Chauhan D, McMillin DW, Klippel S, Laubach JP, Munshi NC, Anderson KC, Richardson PG. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75.
    View in: PubMed
    Score: 0.115
  41. Mitsiades CS, Rouleau C, Echart C, Menon K, Teicher B, Distaso M, Palumbo A, Boccadoro M, Anderson KC, Iacobelli M, Richardson PG. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res. 2009 Feb 15; 15(4):1210-21.
    View in: PubMed
    Score: 0.114
  42. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72.
    View in: PubMed
    Score: 0.109
  43. Munshi NC, Mitsiades C, Richardson PG, Anderson KC. Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. Nat Clin Pract Oncol. 2008 Jul; 5(7):374-5.
    View in: PubMed
    Score: 0.108
  44. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007 Aug; 7(8):585-98.
    View in: PubMed
    Score: 0.102
  45. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist. 2007 Jun; 12(6):664-89.
    View in: PubMed
    Score: 0.101
  46. Munshi NC, Mitsiades CS, Richardson PG, Anderson KC. Does maintenance therapy with thalidomide benefit patients with multiple myeloma? Nat Clin Pract Oncol. 2007 Jul; 4(7):394-5.
    View in: PubMed
    Score: 0.101
  47. Richardson PG, Hideshima T, Mitsiades C, Anderson KC. The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw. 2007 Feb; 5(2):149-62.
    View in: PubMed
    Score: 0.099
  48. Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, Munshi N, Anderson K. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23.
    View in: PubMed
    Score: 0.098
  49. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007 Apr 15; 109(8):3177-88.
    View in: PubMed
    Score: 0.098
  50. Richardson PG, Mitsiades C, Ghobrial I, Anderson K. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 2006 Nov; 18(6):598-608.
    View in: PubMed
    Score: 0.097
  51. Richardson PG, Mitsiades CS, Munshi NC, Anderson KC. Can thalidomide improve outcome in patients with multiple myeloma? Nat Clin Pract Oncol. 2006 Nov; 3(11):590-1.
    View in: PubMed
    Score: 0.097
  52. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2006 Aug; 6(8):1165-73.
    View in: PubMed
    Score: 0.095
  53. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64.
    View in: PubMed
    Score: 0.095
  54. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle. 2005 Feb; 4(2):290-6.
    View in: PubMed
    Score: 0.086
  55. Richardson PG, Mitsiades CS, Hideshima T, Anderson KC. Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol. 2005; 18(4):619-34.
    View in: PubMed
    Score: 0.085
  56. Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, Weller E, Mitsiades C, Hideshima T, Davies F, Doss D, Freeman A, Bosch J, Patin J, Knight R, Zeldis J, Dalton W, Anderson K. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004 Jul; 79(7):875-82.
    View in: PubMed
    Score: 0.083
  57. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004 Mar; 5(3):221-30.
    View in: PubMed
    Score: 0.081
  58. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003 Dec 15; 102(13):4504-11.
    View in: PubMed
    Score: 0.078
  59. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003 May 15; 101(10):4055-62.
    View in: PubMed
    Score: 0.075
  60. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15; 101(6):2377-80.
    View in: PubMed
    Score: 0.074
  61. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002 Nov 01; 100(9):3063-7.
    View in: PubMed
    Score: 0.074
  62. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14374-9.
    View in: PubMed
    Score: 0.073
  63. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30.
    View in: PubMed
    Score: 0.072
  64. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86.
    View in: PubMed
    Score: 0.071
  65. Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, Anderson KC, Richardson PG. The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics. 2018 12; 15(12):1033-1052.
    View in: PubMed
    Score: 0.056
  66. Cholujova D, Bujnakova Z, Dutkova E, Hideshima T, Groen RW, Mitsiades CS, Richardson PG, Dorfman DM, Balaz P, Anderson KC, Jakubikova J. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol. 2017 12; 179(5):756-771.
    View in: PubMed
    Score: 0.052
  67. Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades C, Viselli S, Neuwirth R, Esseltine DL, Anderson K, Ghobrial IM, San Miguel JF, Richardson PG, Tomasson MH, Michor F. Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214.
    View in: PubMed
    Score: 0.046
  68. Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
    View in: PubMed
    Score: 0.044
  69. Zhu D, Wang Z, Zhao JJ, Calimeri T, Meng J, Hideshima T, Fulciniti M, Kang Y, Ficarro SB, Tai YT, Hunter Z, McMilin D, Tong H, Mitsiades CS, Wu CJ, Treon SP, Dorfman DM, Pinkus G, Munshi NC, Tassone P, Marto JA, Anderson KC, Carrasco RD. The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80.
    View in: PubMed
    Score: 0.044
  70. Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, Varga C, Mitsiades CS, Paba-Prada C, Schlossman R, Munshi N, Anderson KC, Richardson PP, Weller E, Ghobrial IM. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8.
    View in: PubMed
    Score: 0.043
  71. Dowling P, Hayes C, Ting KR, Hameed A, Meiller J, Mitsiades C, Anderson KC, Clynes M, Clarke C, Richardson P, O'Gorman P. Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. BMC Genomics. 2014 Oct 17; 15:904.
    View in: PubMed
    Score: 0.042
  72. O'Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O'Gorman P. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol. 2013 May; 71(5):1357-68.
    View in: PubMed
    Score: 0.038
  73. Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, Anderson KC, Munshi NC. Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; 190(3):1360-71.
    View in: PubMed
    Score: 0.037
  74. Rosovsky R, Hong F, Tocco D, Connell B, Mitsiades C, Schlossman R, Ghobrial I, Lockridge L, Warren D, Bradwin G, Doyle M, Munshi N, Soiffer RJ, Anderson KC, Weller E, Richardson P. Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
    View in: PubMed
    Score: 0.037
  75. Lawasut P, Chauhan D, Laubach J, Hayes C, Fabre C, Maglio M, Mitsiades C, Hideshima T, Anderson KC, Richardson PG. New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012 Dec; 7(4):258-66.
    View in: PubMed
    Score: 0.037
  76. Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012 Dec 13; 120(25):5002-13.
    View in: PubMed
    Score: 0.036
  77. Rickles RJ, Tam WF, Giordano TP, Pierce LT, Farwell M, McMillin DW, Necheva A, Crowe D, Chen M, Avery W, Kansra V, Nawrocki ST, Carew JS, Giles FJ, Mitsiades CS, Borisy AA, Anderson KC, Lee MS. Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. Mol Cancer Ther. 2012 Jul; 11(7):1432-42.
    View in: PubMed
    Score: 0.035
  78. Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
    View in: PubMed
    Score: 0.035
  79. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
    View in: PubMed
    Score: 0.034
  80. Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
    View in: PubMed
    Score: 0.034
  81. Siegel D, Jagannath S, Vesole DH, Borello I, Mazumder A, Mitsiades C, Goddard J, Dunbar J, Normant E, Adams J, Grayzel D, Anderson KC, Richardson P. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2011 Dec; 52(12):2308-15.
    View in: PubMed
    Score: 0.034
  82. Rajpal R, Dowling P, Meiller J, Clarke C, Murphy WG, O'Connor R, Kell M, Mitsiades C, Richardson P, Anderson KC, Clynes M, O'Gorman P. A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics. 2011 Apr; 11(8):1391-402.
    View in: PubMed
    Score: 0.033
  83. Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol. 2011 Feb; 4(1):51-60.
    View in: PubMed
    Score: 0.033
  84. Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG. Tanespimycin as antitumor therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):17-22.
    View in: PubMed
    Score: 0.033
  85. Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, Lahuerta JJ, García-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Bladé J, San Miguel J. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res. 2010 Jun 15; 16(12):3260-9.
    View in: PubMed
    Score: 0.031
  86. Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M, Richardson P. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica. 2010 Jul; 95(7):1144-9.
    View in: PubMed
    Score: 0.030
  87. Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
    View in: PubMed
    Score: 0.030
  88. Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 01; 15(23):7153-60.
    View in: PubMed
    Score: 0.030
  89. Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
    View in: PubMed
    Score: 0.030
  90. Laubach JP, Mitsiades CS, Hideshima T, Schlossman R, Chauhan D, Munshi N, Ghobrial I, Carreau N, Anderson KC, Richardson PG. Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
    View in: PubMed
    Score: 0.030
  91. Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25.
    View in: PubMed
    Score: 0.029
  92. Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, Mitsiades C, Anderson KC, Colditz GA. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):282-8.
    View in: PubMed
    Score: 0.028
  93. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008 Mar; 49(3):502-7.
    View in: PubMed
    Score: 0.027
  94. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood. 2002 Mar 15; 99(6):2162-71.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.